HOME >> BIOLOGY >> NEWS
Vaccine protects against fatal West Nile complication

A vaccine already approved in the United States to prevent a related disease protects experimental animals and may also protect people from the most serious complication associated with West Nile virus infection, say researchers from the University of Texas Medical Branch at Galveston (UTMB).

They report their findings today at the 50th Annual Meeting of the American Society of Tropical Medicine and Hygiene in Atlanta.

Dr. Robert Tesh, a professor in the Center for Tropical Diseases at UTMB and his colleagues tested two vaccines for Japanese encephalitis (JE) for their its ability to protect hamsters from the fatal encephalitis (inflammation of the brain) that is associated with West Nile viral infection.

The JE virus is a flavivirus, a member of the same viral family as the West Nile virus, dengue virus and St. Louis encephalitis virus.

"It looks like the West Nile virus is spreading throughout the Western Hemisphere and it will probably go all the way through the tropics and down to Argentina says Tesh.

In the United States we haven't had much exposure to flaviviruses; but we wanted to see what could happen when the West Nile virus reached an area like Central America where people have already had exposure to other flaviviruses, either through infection or vaccination.

Previous studies in India have suggested that prior infection with the JE virus will protect monkeys from fatal West Nile infections. In this study Tesh and his colleagues first inoculated hamsters with one of three flavivirus vaccines: a live-attenuated JE vaccine currently used on millions of people in China, a killed-virus JE vaccine currently approved for use in the United States and a yellow fever vaccine.

"If we infect hamsters with the New York strain of West Nile virus about half will die of encephalitis if they have not had a previous flavivirus infection," says Tesh. But in the case of the JE-vaccinated hamsters "none of them
'"/>

Contact: Jim Sliwa
jsliwa@asmusa.org
202-942-9297
American Society for Microbiology
14-Nov-2001


Page: 1 2

Related biology news :

1. Hope Clinic of Emory Vaccine Center receives CDC contract
2. Vaccines against foodborne disease on horizon
3. GenVec, U.S. NMRC, and PATHs Malaria Vaccine Initiative partner to expand malaria vaccine efforts
4. Vaccine technique shows potential against common form of lung cancer
5. Fighting fire with fire? Vaccine based on chimp virus shows promise against HIV
6. Emory Vaccine Research Center study identifies specific gene required for long-term immunity
7. Vaccine prevents stroke in rats
8. Vaccine puts blood-sucking ticks off their food
9. Dr. Robert C. Gallo to Collaborate with Visiting Israeli Scientist on Promising HIV Vaccine Research at Marylands Institute of Human Virology
10. Vaccine controls AIDS in monkeys, researchers report in Science
11. Vaccine put into tomatoes shows promise fighting virus in lab tests

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Vaccine protects against fatal West Nile complication

(Date:10/18/2014)... suspected genetic conditions, a certain type of exome sequencing ... than traditional molecular diagnostic methods, according to a study ... released to coincide with the American Society of Human ... protein­coding region of the genome (the complete set of ... organism), has been rapidly applied in research settings and ...
(Date:10/17/2014)... release is available in German . ... of sperms every day in order to reproduce? And why ... the topic of the latest issue of the research journal ... The evolutionary biologist Steven Ramm from Bielefeld University Bielefeld has ... is not unusual for a female to copulate with several ...
(Date:10/17/2014)... To date, antidotes ... doctors are often limited to supportive therapy such as induced ... of drugs involved. So what can be done if a ... professor Jean-Christophe Leroux from the Institute of Pharmaceutical Sciences at ... "The task was to develop an agent that could eliminate ...
Breaking Biology News(10 mins):Study examines type of exome sequencing and molecular diagnostic yield 2Study examines type of exome sequencing and molecular diagnostic yield 3Sperm wars 2Emergency aid for overdoses 2Emergency aid for overdoses 3
(Date:10/22/2014)... Oct. 22, 2014   Synthetic Biologics, Inc. ... therapies for serious infections and diseases, announced today that ... Notice of Allowance for a composition of matter patent ... difficile program, SYN-004. This is Synthetic Biologics, first ... U.S. and adds to the Company,s extensive C. ...
(Date:10/22/2014)... and HONG KONG , Oct. ... disease therapeutics enterprise, announced today that rare disease expert ... as vice president, research. Dr. McKew brings more than ... leadership positions at the National Institutes of Health, Wyeth ... by Wyeth). Dr. McKew will lead aTyr,s efforts to expand ...
(Date:10/20/2014)... 20, 2014 Asterias Biotherapeutics, Inc. (NYSE ... signed a Notice of Grant Award (NGA) with ... October 1, 2014.  The NGA provides for the ... release of additional grant funds pursuant to the ... clinical development of Asterias, product, AST-OPC1. The grant ...
(Date:10/20/2014)... BOSTON , Oct. 20, 2014 ... commercialization company tackling big healthcare problems, announced today ... investment round, with participation from Invesco Perpetual, a ... be used to drive PureTech,s existing pipeline forward ... technologies. "PureTech has the scientific creativity to really ...
Breaking Biology Technology:Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 2Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 4aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 2PureTech Announces Expansion with Oversubscribed $55M Funding Round 3PureTech Announces Expansion with Oversubscribed $55M Funding Round 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 5PureTech Announces Expansion with Oversubscribed $55M Funding Round 6
Cached News: